Free Trial

BioLife Solutions, Inc. (NASDAQ:BLFS) Given Consensus Rating of "Buy" by Brokerages

BioLife Solutions logo with Medical background

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) has received an average recommendation of "Buy" from the seven research firms that are covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $29.43.

Several equities research analysts recently commented on the company. KeyCorp increased their price target on BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a report on Friday, December 13th. Northland Securities increased their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a report on Wednesday, January 8th. Benchmark reaffirmed a "buy" rating and issued a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. TD Cowen increased their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Finally, HC Wainwright lowered their price objective on BioLife Solutions from $29.00 to $27.00 and set a "buy" rating for the company in a research report on Monday, November 18th.

Get Our Latest Research Report on BLFS

BioLife Solutions Price Performance

Shares of BioLife Solutions stock traded down $0.31 during mid-day trading on Friday, reaching $26.14. 146,801 shares of the stock traded hands, compared to its average volume of 265,856. BioLife Solutions has a fifty-two week low of $14.50 and a fifty-two week high of $28.88. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $1.21 billion, a PE ratio of -24.66 and a beta of 1.92. The business has a 50-day moving average of $26.09 and a 200 day moving average of $24.55.

Insider Transactions at BioLife Solutions

In other news, EVP Aby J. Mathew sold 25,000 shares of the firm's stock in a transaction on Friday, November 15th. The stock was sold at an average price of $21.17, for a total transaction of $529,250.00. Following the completion of the transaction, the executive vice president now directly owns 302,046 shares in the company, valued at $6,394,313.82. This trade represents a 7.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Troy Wichterman sold 987 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the sale, the chief financial officer now owns 121,779 shares in the company, valued at approximately $3,290,468.58. The trade was a 0.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 103,129 shares of company stock worth $2,344,018 over the last ninety days. Company insiders own 2.20% of the company's stock.

Institutional Trading of BioLife Solutions

Hedge funds have recently modified their holdings of the stock. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of BioLife Solutions in the third quarter valued at $28,000. Quest Partners LLC acquired a new stake in shares of BioLife Solutions in the third quarter valued at $57,000. GAMMA Investing LLC raised its stake in shares of BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider's stock valued at $83,000 after acquiring an additional 748 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of BioLife Solutions in the second quarter valued at $122,000. Finally, Summit Global Investments acquired a new stake in shares of BioLife Solutions in the third quarter valued at $228,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

(Get Free Report

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Read More

Analyst Recommendations for BioLife Solutions (NASDAQ:BLFS)

Should You Invest $1,000 in BioLife Solutions Right Now?

Before you consider BioLife Solutions, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.

While BioLife Solutions currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines